MCM
RARE icon

Moore Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Moore Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$7.27M – 715
2025
Q2 		$7.27M Buy
+200,000
New +$7.21M 0.09% 171

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Moore Capital Management's RARE Position: Q1 2026 in Review

Moore Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 21% in Q1 2026, selling an estimated $965K and leaving 157,132 shares worth $3.29M. The position accounts for 0.07% of the portfolio, ranked #215.

Moore Capital Management first reported a position in RARE in Q1 2015 and has held it in 15 quarters since. The position peaked at $13.6M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Moore Capital Management held 157,132 shares of Ultragenyx Pharmaceutical worth $3.29M as of Q1 2026.
  • Moore Capital Management sold 42,868 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $965K.
  • Ultragenyx Pharmaceutical made up 0.07% of Moore Capital Management's portfolio in Q1 2026, its #215 holding.
  • Moore Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 15 quarters since.
  • Moore Capital Management's Ultragenyx Pharmaceutical position peaked at $13.6M in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.